Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer

Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer

Background: The progression and metastasis of tumors are typically accompanied by angiogenesis. Crucially, vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) play a significant role in tumor-associated angiogenesis. In this study, the aim was to investigate the antitumor effect of...

Full description

Bibliographic Details
Main Authors:	Min Yan, Ronghao Yang, Qi Li, Chenjie Wang, Jiali Chen, Zhenying Wu, Han Li, Juan Fan
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Series:	Translational Oncology
Subjects:	Anti-angiogenesis Anlotinib Bevacizumab Multi-target treatment Colorectal cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523324000135

Similar Items

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
by: Zhujun Liu, et al.
Published: (2022-05-01)

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
by: Shenglong Li, et al.
Published: (2021-05-01)

Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells
by: Lijun Liang, et al.
Published: (2019-02-01)

Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
by: Liu J, et al.
Published: (2019-11-01)

Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade
by: Yang Q, et al.
Published: (2020-06-01)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
by: Caiyun Nie, et al.
Published: (2022-07-01)

Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial
by: Shuangshuang Zhao, et al.
Published: (2024-01-01)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
by: Fenge Jiang, et al.
Published: (2022-09-01)

Intratumoral injection of anlotinib hydrogel enhances antitumor effects and reduces toxicity in mouse model of lung cancer
by: Qin Gao, et al.
Published: (2020-01-01)

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
by: Frontiers Production Office
Published: (2022-11-01)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
by: Yingbo Shao, et al.
Published: (2022-07-01)

Response of Lung Adenocarcinoma Harbouring Sensitizing EGFR Mutation to the Fourth-line Combination Treatment of Pembrolizumab and Anlotinib
by: Liling HUANG, et al.
Published: (2021-10-01)

Monitoring antiangiogenesis of bevacizumab in zebrafish
by: Zhang J, et al.
Published: (2018-08-01)

Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab
by: Neel Patel, et al.
Published: (2017-05-01)

Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
by: Min Yuan, et al.
Published: (2021-10-01)

Enhancement of radiation response with bevacizumab
by: Hoang Tien, et al.
Published: (2012-04-01)

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
by: Min Yuan, et al.
Published: (2022-01-01)

Pembrolizumab enhances the anti-pancreatic cancer activity of anlotinib
by: Kang Mafei, et al.
Published: (2022-03-01)

Genetic Variants of <i>ANGPT1</i>, <i>CD39</i>, <i>FGF2</i> and <i>MMP9</i> Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer
by: María Gaibar, et al.
Published: (2021-01-01)

Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report
by: Nan Jin, et al.
Published: (2022-04-01)

Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
by: Yolla Haibe, et al.
Published: (2020-02-01)

Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy
by: Rahmawati Minhajat, et al.
Published: (2021-05-01)

CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib
by: Haosheng Li, et al.
Published: (2024-03-01)

Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib
by: Li S, et al.
Published: (2023-11-01)

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
by: Jingzhen Shi, et al.
Published: (2020-07-01)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
by: Cui Q, et al.
Published: (2021-01-01)

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
by: Nanlin Hu, et al.
Published: (2021-08-01)

Corrigendum: Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
by: Jingzhen Shi, et al.
Published: (2020-11-01)

Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis
by: Yanghui Zhu, et al.
Published: (2022-12-01)

TWO PROGRAMS OF CHEMOTHERAPY IN COMBINATION WITH BEVACIZUMAB IN THE TREATMENT OF DISSEMINATED COLORECTAL CANCER
by: O. V. Zharkova, et al.
Published: (2015-02-01)

Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling
by: Xiaoling Zhang, et al.
Published: (2020-05-01)

Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
by: Antonia Martinetti, et al.
Published: (2014-08-01)

Preliminary results of an observational program for estimating the duration of bevacizumab therapy in patients with metastatic colorectal cancer in daily clinical practice
by: I V Poddubnaya, et al.
Published: (2013-03-01)

Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study
by: Bai H, et al.
Published: (2024-02-01)

The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects
by: Chih-Lin Mao, et al.
Published: (2022-06-01)

Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trialResearch in context
by: Yan Liang, et al.
Published: (2024-05-01)

Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma
by: Mei Luo, et al.
Published: (2021-12-01)

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
by: Di Wu, et al.
Published: (2019-07-01)

Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study
by: Reem D. Mahmood, et al.
Published: (2021-04-01)

The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer
by: Brigida Anna Maiorano, et al.
Published: (2022-10-01)